|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.043 USD | +13.16% |
|
-2.27% | +95.45% |
| 04-15 | Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
| 03-12 | Cell MedX Corp. announced that it has received $0.075 million in funding | CI |
Cell MedX Corp. announced the formation of an Advisory Board with Dr. John Sanderson MD as its Chairman. Dr. Sanderson will be organizing the development team and protocols necessary to advance the development of the company's proposed technology, including the clinical trial phases and oversight of the results of those trials.
Dr. Sanderson is accepting this appointment as an interim position in the anticipation of joining the company as its Chief Medical Director.
| 1st Jan change | Capi. | |
|---|---|---|
| +95.45% | 12.78M | |
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
CELL MEDX CORP. 